Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients - 10/10/20
Funding sources: None. |
|
Conflicts of interest: Professor Sinclair has served as a consultant or paid speaker for, or participated in clinical trials sponsored by, LEO Pharma, Amgen, Novartis, Merck & Co, Celgene, Coherus Biosciences, Janssen, Regeneron, MedImmune, GlaxoSmithKline, Cutanea, Samson Clinical, Boehringer Ingelheim, Pfizer, MSD, Oncobiologics, Roche, Eli Lilly, and Bayer. Dr Wall has served as a consultant or paid speaker for Janssen and Eli Lilly and received a travel grant from Pfizer. Authors Ismail, Meah, Trindade de Carvalho, and Bhoyrul have no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Vol 83 - N° 5
P. 1478-1479 - novembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?